Skip to main content

Ortivus AB (publ) interim report for the period April – June 2023

2023-08-25 08:30

Expanding Ortivus’ product range with new applications.

Significant events for the period April – June 2023

  • Ortivus is awarded a contract for the delivery of equipment to the ambulance and hospital operations of Region Kronoberg. The contract pertains to the delivery of Ortivus’ solution MobiMed Life, semi-automatic and manual defibrillators. The order value is estimated to be 4.9 MSEK, and the contract duration is 2 years with a potential extension of 1+1 years.
  • Ortivus qualifies for the NHS framework agreement concerning MobiMed Life, creating new opportunities in the United Kingdom.
  • Ortivus’ product range is further expanded through an asset acquisition of the vehicle control system FleetCtrl, which, together with Ortivus’ other solutions, constitutes a competitive total solution for the future of healthcare.

Significant events after end of the period

  • Ortivus has entered into a contract to supply MobiMed ePR and MobiMed enRoute to support the ambulance operations of Region Jönköpings län. The contract duration is 5 years, with the possibility of an extension for another 5 years. The order value amounts to 4.2 MSEK during the initial contract period, and an additional 4.2 MSEK in the event of a contract extension.
  • A subcontractor responsible for the data operation of MobiMed ePR falls victim to a criminal cyberattack, affecting some of the company’s British clients. The system is isolated, and the application becomes unavailable for a period of time.
  • Ortivus enters into an agreement with the company’s main shareholder, Ponderus Invest, covering a credit line of 8.0 MSEK. The company’s liquidity is being strengthened to effectively manage prolonged procurement processes, delayed deliveries, and customer payments.

April – June 2023

  • Net sales amounted to 20.7 (26.4) MSEK.
  • The gross margin amounted to 37% (57%).
  • EBITDA amounted to -4.8 (3.5) MSEK.
  • Earnings after tax per share before and after dilution amounted to -0.11 (0.08) SEK.
  • Operating cash flow before changes in working capital amounted to -4.3 (8.9) MSEK.

January – June 2023

  • Net sales amounted to 48.7 (51.0) MSEK.
  • The gross margin amounted to 43% (53%).
  • EBITDA amounted to -4.6 (5.5) MSEK.
  • Earnings after tax per share before and after dilution amounted to -0.10 (0.12) SEK.
  • Operating cash flow before changes in working capital amounted to -2.8 (0.8) MSEK.
Apr-Jun 2023 Apr-Jun 2022 Jan-Jun 2023 Jan-Jun 2022 Jan-Dec 2022
Net sales (MSEK) 20.7 26.4 48.7 51.0 104.5
Gross margin (%) 37% 57% 43% 53% 47%
Operating profit (MSEK) -4.7 3.5 -4.2 5.5 5.8
Operating margin (%) -23% 13% -9% 11% 6%
EBITDA (MSEK) -3.5 4.4 -2.0 6.8 10.2

Get in touch

Empower your team with smarter tools

Discover why leading healthcare organisations are choosing Ortivus.

Get contacted

Fill in the form and one of our sales representatives will contact you as soon as possible.

Required